home / stock / ctmx / ctmx news

CTMX News and Press, CytomX Therapeutics Inc. From 05/09/24

Stock Information
Company Name: CytomX Therapeutics Inc.
Stock Symbol: CTMX
Market: NASDAQ
Website: cytomx.com
Menu
CTMX CTMX Quote CTMX Short CTMX News CTMX Articles CTMX Message Board
Get CTMX Alerts

News, Short Squeeze, Breakout and More Instantly...
CTMX - US Companies Moving the Markets, Evening edition
Thu, May 09, 2024 as of 4:00 pm ET

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 20.3% to $0.0699 on volume of 164,902,840 shares Safe and Green Development Corporation (SGD) rose 36.7% to $0.8477 on volume of 100,466,382 shares PROSHARES TRUST (SQQQ) fell 0.6% to $1...
CTMX - CCLD, SKYT and SEED among mid-day movers

2024-05-09 13:12:57 ET More on mid-day movers & stocks. SkyWater Earnings Preview: Products In High Demand CareCloud, Inc. (CCLD) Q4 2023 Earnings Call Transcript SkyWater Technology, Inc. 2023 Q4 - Results - Earnings Call Presentation SkyWater Technology...

CTMX - CytomX slides after early data for Amgen-partnered cancer drug

2024-05-09 11:33:48 ET More on Amgen, CytomX, etc. CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript Amgen Could Become A Real Contender In The Obesity Market Amgen's Q1 Earnings: Solid All Court Progress, Major Weight Loss Catalyst Pending Cy...

CTMX - Tivic Health, RAPT Therapeutics, Notable Labs among healthcare movers

2024-05-09 10:00:35 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 16 out...
CTMX - US Companies Moving the Markets, Morning edition
Thu, May 09, 2024 as of 10.00 am ET

A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 22.2% to $0.071 on volume of 95,914,661 shares Pop Culture Group Co. Ltd (CPOP) rose 128.8% to $3.89 on volume of 39,763,492 shares Safe and Green Development Corporation (SGD) rose 40.7...

CTMX - CytomX Therapeutics, Inc. (CTMX) Q1 2024 Earnings Call Transcript

2024-05-08 21:22:10 ET CytomX Therapeutics, Inc. (CTMX) Q1 2024 Results Conference Call May 08, 2024 05:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Wayne Chu - Chie...

CTMX - DUOL, CDLX and LFMD are among after hour movers

2024-05-08 17:38:27 ET Gainers: CytomX Therapeutics  ( CTMX ) +77% . Tarsus Pharmaceuticals ( TARS ) +15% . ZimVie  ( ZIMV ) +13% . Equinix ( EQIX ) +11% . Consensus Cloud Solutions ( CCSI ) +10% . Losers: Cardl...
CTMX - CytomX GAAP EPS of $0.17 beats by $0.24, revenue of $41.46M beats by $19.74M

2024-05-08 16:34:08 ET More on CytomX CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript Cyt...

CTMX - CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

- Company announces positive initial Phase 1a dose escalation data for monotherapy CX-904 (EGFRxCD3 T-cell engager) in solid tumors - - First dose cohort cleared in Phase 1 clinical study of CX-2051, an EpCAM Targeting PROBODY ® ADC, in solid tumors. Initial data anticipated in...

CTMX - CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial signs of efficacy observed for CX-904 in advanced pancreatic cancer, including 2 of 6 pat...
Previous 10 Next 10